SCHEMBL2913992

SCHEMBL2913992

N#CCCN1CCC(c2ccc(C(N)=O)c(C3=CCCCC3)c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 14/20 0.59
KIT P10721 12/20 0.53
NTRK1 P04629 3/20 0.49
LCK P06239 3/20 0.49
AXL P30530 3/20 0.49
FLT3 P36888 3/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2C19 P33261 3/20 0.43
KCNH2 Q12809 1/20 0.43
BMPR1B O00238 1/20 0.41
PLK4 O00444 1/20 0.41
STK25 O00506 1/20 0.41
RIOK3 O14730 1/20 0.41
CHEK1 O14757 1/20 0.41
GAK O14976 1/20 0.41
DCLK1 O15075 1/20 0.41
MUSK O15146 1/20 0.41
EPHB6 O15197 1/20 0.41
PDPK1 O15530 1/20 0.41
MAP3K13 O43283 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3069634 0.94 KIT (0.56) CSF1RKITNTRK1LCKAXL
SCHEMBL2908131 0.88 CSF1R (0.55) CSF1RKITNTRK1LCKAXL
SCHEMBL2913135 0.86 CSF1R (0.56) CSF1RKITNTRK1LCKAXL
SCHEMBL2915999 0.86 CSF1R (0.58) CSF1RKITNTRK1LCKAXL
SCHEMBL3081024 0.86 CSF1R (0.58) CSF1RKITNTRK1LCKAXL
SCHEMBL5074829 0.84 CSF1R (0.45) CSF1RKITNTRK1LCKAXL
SCHEMBL2913417 0.84 KIT (0.59) CSF1RKITNTRK1LCKAXL
Trifluoroacetic Acid SCHEMBL3069637 0.83 KIT (0.58) CSF1RKITNTRK1LCKAXL
Trifluoroacetic Acid SCHEMBL3086036 0.82 CSF1R (0.50) CSF1RKITNTRK1LCKAXL
Trifluoroacetic Acid SCHEMBL3090439 0.81 CSF1R (0.51) CSF1RKITNTRK1LCKAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 EP claimed
US-7662837-B2 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-16 US claimed
EP-1951234-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 EP claimed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP claimed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 WO claimed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US claimed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US claimed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
EP-3559006-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES Arvinas Operations, Inc. (US) 2019-10-30 EP disclosed
WO-2018118598-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES Arvinas, Inc. (US) 2018-06-28 WO disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 US disclosed
US-8933091-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2015-01-13 US disclosed
US-8697716-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2014-04-15 US disclosed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 WO disclosed
WO-2006138155-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 WO disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES CSF1R 34/4885KIT 125/4885NTRK1 156/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R CSF1R 3/4885KIT 70/4885NTRK1 1339/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES CSF1R 34/4885KIT 125/4885NTRK1 156/4885
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 CSF1R 2973/4885KIT 1/4885NTRK1 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.